MEDIA ADVISORY | 2025 NAAG Presidential Initiative Summit
The National Association of Attorneys General (NAAG) invites members of the press to attend the public portion of the 2025 Presidential Initiative Summit:—“Building on Opioid Litigation Success: AGs Leading the Fight Against Substance Abuse and Drug Trafficking”. This summit is a national platform for exchanging best practices and driving collective impact.
Coalition of State and Territory Attorneys General Support Bipartisan Legislation to Prevent Youth Substance Use
The coalition of attorneys general stressed that youth substance use remains a growing public health and public safety concern—especially in light of the rise in fentanyl-related overdoses and the increasing availability of synthetic drugs.
39 State and Territory Attorneys General Support Bipartisan Legislation to Prevent Youth Substance Use
The coalition emphasizes the critical role of the LSC in ensuring that the legal system works for all Americans, particularly those who face economic barriers to adequate legal counsel.
Attorneys General Urge Congress to Preserve Access to Health Care for 9/11 Responders and Survivors
The coalition is calling on Congress to act swiftly and decisively to ensure WTCHP has the full funding it needs.
39 Attorneys General Urge Congress to Address Funding Crisis Affecting the World Trade Center Health Program
The coalition emphasizes the critical role of the LSC in ensuring that the legal system works for all Americans, particularly those who face economic barriers to adequate legal counsel.
State and Territory Attorneys General Urge FDA to Take Action Against Counterfeit and Illegally Sold GLP-1 Drugs
Washington, D.C.– The National Association of Attorneys General (NAAG) sent a letter on behalf of a bipartisan coalition of 38 state and territory attorneys general which calls on the Food and Drug Administration (FDA) to take decisive action against the unlawful sale and distribution of counterfeit and illegally sold GLP-1 drugs, including Mounjaro, Zepbound, Ozempic, and…
